Treatment choice for diabetic macular edema
- PMID: 25692914
- DOI: 10.1056/NEJMe1500351
Treatment choice for diabetic macular edema
Comment in
-
Targeting the Effect of VEGF in Diabetic Macular Edema.N Engl J Med. 2015 Jul 30;373(5):481. doi: 10.1056/NEJMc1505684. N Engl J Med. 2015. PMID: 26222569 No abstract available.
-
Targeting the Effect of VEGF in Diabetic Macular Edema.N Engl J Med. 2015 Jul 30;373(5):482. doi: 10.1056/NEJMc1505684. N Engl J Med. 2015. PMID: 26230004 No abstract available.
Comment on
-
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.N Engl J Med. 2015 Mar 26;372(13):1193-203. doi: 10.1056/NEJMoa1414264. Epub 2015 Feb 18. N Engl J Med. 2015. PMID: 25692915 Free PMC article. Clinical Trial.
Similar articles
-
Targeting the Effect of VEGF in Diabetic Macular Edema.N Engl J Med. 2015 Jul 30;373(5):482. doi: 10.1056/NEJMc1505684. N Engl J Med. 2015. PMID: 26230004 No abstract available.
-
Targeting the Effect of VEGF in Diabetic Macular Edema.N Engl J Med. 2015 Jul 30;373(5):481. doi: 10.1056/NEJMc1505684. N Engl J Med. 2015. PMID: 26222569 No abstract available.
-
Targeting the Effect of VEGF in Diabetic Macular Edema.N Engl J Med. 2015 Jul 30;373(5):480-1. doi: 10.1056/NEJMc1505684. N Engl J Med. 2015. PMID: 26222568 No abstract available.
-
Anti-VEGF Molecules for the Management of Diabetic Macular Edema.Curr Pharm Des. 2015;21(32):4731-7. doi: 10.2174/1381612821666150909095756. Curr Pharm Des. 2015. PMID: 26350530 Review.
-
Comparative effectiveness of anti-growth factor therapies for diabetic macular edema: summary of primary findings and conclusions.Arch Intern Med. 2012 Jul 9;172(13):1014-5. doi: 10.1001/archinternmed.2012.2335. Arch Intern Med. 2012. PMID: 22688778 Review. No abstract available.
Cited by
-
Association of Private Equity Firm Acquisition of Ophthalmology Practices with Medicare Spending and Use of Ophthalmology Services.Ophthalmology. 2024 Mar;131(3):360-369. doi: 10.1016/j.ophtha.2023.09.029. Epub 2023 Sep 29. Ophthalmology. 2024. PMID: 37777118
-
Protective Factors and the Pathogenesis of Complications in Diabetes.Endocr Rev. 2024 Mar 4;45(2):227-252. doi: 10.1210/endrev/bnad030. Endocr Rev. 2024. PMID: 37638875 Free PMC article. Review.
-
Targeting angiogenesis in oncology, ophthalmology and beyond.Nat Rev Drug Discov. 2023 Jun;22(6):476-495. doi: 10.1038/s41573-023-00671-z. Epub 2023 Apr 11. Nat Rev Drug Discov. 2023. PMID: 37041221 Review.
-
Changes in retinal and choriocapillaris density in diabetic patients receiving anti-vascular endothelial growth factor treatment using optical coherence tomography angiography.Int J Retina Vitreous. 2019 Dec 10;5:41. doi: 10.1186/s40942-019-0192-9. eCollection 2019. Int J Retina Vitreous. 2019. PMID: 31867124 Free PMC article.
-
One-year outcomes of novel VEGF decoy receptor therapy with intravitreal conbercept in diabetic retinopathy-induced macular edema.Mol Vis. 2019 Oct 21;25:636-644. eCollection 2019. Mol Vis. 2019. PMID: 31700228 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical